Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ CARA opened at $0.27 on Friday. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.40. The company has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.45. The firm has a market capitalization of $14.54 million, a P/E ratio of -0.12 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. As a group, equities research analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN raised its stake in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after acquiring an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned approximately 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.